Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

AAV-mediated factor IX gene transfer as a therapy for hemophilia B

June 8, 2000

Genentech's single-injection clot buster for heart attack approved by FDA

June 7, 2000

Akzo Nobel's new thrombin inhibitors presented in patent literature

June 6, 2000

Early results from first hemophilia B AAV-mediated gene therapy study

June 6, 2000

Abciximab complements PTCA in patients with AMI

June 6, 2000

Antibodies to von Willebrand factor that act only at sites of thrombus formation

June 2, 2000

PI-88 under development for cardiovascular indication; Progen enters strategic alliance

June 2, 2000

Orally bioavailable thrombin inhibitors designed at Pfizer

June 1, 2000

Antiplatelet effects reported for new cell adhesion inhibitors from Takeda

June 1, 2000

Angiomax approvable for use as anticoagulant

May 26, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...